Next-Generation polio vaccine enters human testing
NCT ID NCT07688369
First seen Jul 07, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This trial tests a new recombinant polio vaccine (rPV) against the current standard IPOL vaccine in healthy adults aged 18 to 60. The goal is to see if the new vaccine is safe and triggers a strong immune response. It is a small, early-stage study to gather initial data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Recombinant Poliomyelitis Vaccine (rPV)
- What this could lead to
- If successful, this could lead to a more modern, potentially easier-to-produce polio vaccine to help maintain global polio immunity.
- What could go wrong
- This is an early phase 1 trial with only 36 healthy adults, so safety and immune response are still being tested. The vaccine may not work as well as the current one or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLIO IMMUNITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Doherty Clinical Trials Limited
East Melbourne, Victoria, 3002, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••